Nature Communications (Jul 2024)

A(H2N2) and A(H3N2) influenza pandemics elicited durable cross-reactive and protective antibodies against avian N2 neuraminidases

  • Zaolan Liang,
  • Xia Lin,
  • Lihong Sun,
  • Kimberly M. Edwards,
  • Wenjun Song,
  • Hailiang Sun,
  • Yanmin Xie,
  • Fangmei Lin,
  • Shiman Ling,
  • Tingting Liang,
  • Biying Xiao,
  • Jiaqi Wang,
  • Min Li,
  • Chin-Yu Leung,
  • Huachen Zhu,
  • Nisha Bhandari,
  • Raghavan Varadarajan,
  • Min Z. Levine,
  • Malik Peiris,
  • Robert Webster,
  • Vijaykrishna Dhanasekaran,
  • Nancy H. L. Leung,
  • Benjamin J. Cowling,
  • Richard J. Webby,
  • Mariette Ducatez,
  • Mark Zanin,
  • Sook-San Wong

DOI
https://doi.org/10.1038/s41467-024-49884-9
Journal volume & issue
Vol. 15, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Human cases of avian influenza virus (AIV) infections are associated with an age-specific disease burden. As the influenza virus N2 neuraminidase (NA) gene was introduced from avian sources during the 1957 pandemic, we investigate the reactivity of N2 antibodies against A(H9N2) AIVs. Serosurvey of healthy individuals reveal the highest rates of AIV N2 antibodies in individuals aged ≥65 years. Exposure to the 1968 pandemic N2, but not recent N2, protected against A(H9N2) AIV challenge in female mice. In some older adults, infection with contemporary A(H3N2) virus could recall cross-reactive AIV NA antibodies, showing discernable human- or avian-NA type reactivity. Individuals born before 1957 have higher anti-AIV N2 titers compared to those born between 1957 and 1968. The anti-AIV N2 antibodies titers correlate with antibody titers to the 1957 N2, suggesting that exposure to the A(H2N2) virus contribute to this reactivity. These findings underscore the critical role of neuraminidase immunity in zoonotic and pandemic influenza risk assessment.